Last reviewed · How we verify

NCT04035122: Lokophysio

Physiological Responses in Robotic Neurorehabilitation

Status unknown NA Last updated 17 February 2020
What this trial tests

NA trial testing Robotic Treatment in Interventional Study in 100 participants. Status unknown.

Timeline
1 August 2019
Primary endpoint
31 May 2020
31 July 2020

Quick facts

Lead sponsorIRCCS Centro Neurolesi Bonino Pulejo
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment100
Start date1 August 2019
Primary completion31 May 2020
Estimated completion31 July 2020
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Centro Neurolesi Bonino Pulejo — full company profile →

Who can join

Adults 18 to 75, any sex, with Interventional Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Robotic rehabilitation is very useful for improving functional recovery in neurological patients, there is not much evidence on its role in improving physiological responses (i.e. intestinal motility, orthostatic pressure), which are often abnormal in these patients. To this end, we designed a randomized controlled experimental study on neurological patients, with the aim of evaluating the effects of robotic neurorehabilitation using Lokomat on physiological responses, compared to traditional therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Interventional Study

Currently open trials in the same condition.

Other IRCCS Centro Neurolesi Bonino Pulejo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04035122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing